Lynparza’s Olympia win could broaden breast cancer use
The Parp inhibitor registers an unexpected clinical win in the adjuvant setting, but more convincing data might still be needed.
Amicus fail dents Pompe pipeline
Amicus follows Sanofi with disappointing pivotal Pompe data, casting further doubt on approvals.
Pfizer reveals its PD-1 secret
The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.
